10-Propargyl-10-deazaaminopterin
|
|
10-Propargyl-10-deazaaminopterin Eigenschaften
- Schmelzpunkt:
- 215 °C(dec.)
- Dichte
- 1.471±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- Wasserl?slichkeit
- Insoluble in water
- L?slichkeit
- ≥23.85 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
- pka
- 3.53±0.10(Predicted)
- Aggregatzustand
- powder to crystal
- Farbe
- White to Light yellow
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
HS Code | 2933.59.5300 | ||
---|---|---|---|
Giftige Stoffe Daten | 146464-95-1(Hazardous Substances Data) |
Bildanzeige (GHS) |
![]() ![]() |
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alarmwort | Warnung | |||||||||||||||||||||
Gefahrenhinweise |
|
|||||||||||||||||||||
Sicherheit |
|
10-Propargyl-10-deazaaminopterin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Pralatrexate, an injectable DHFR inhibitor, was launched for the treatment of patients with relapsed or refractory PTCL. PTCL is an aggressive form of non-Hodgkin’s lymphoma (NHL) characterized by the proliferation of abnormal T-lymphocytes that circulate in the peripheral bloodstream. The inhibition of the folate enzymes DHFR and thymidylate synthase is a well-validated method of cancer treatment. In vitro, pralatrexate is slightly less potent than MTX in inhibiting DHFR derived from murine leukemia L1210 cells (Ki = 18.2 pM vs. 5.75 pM) and human leukemia CCRF-CEM cells (Ki = 13.4 pM vs. 5.4 pM). However, it is transported into both types of cells with 10-fold higher efficiency than MTX, thereby providing a more potent inhibition of cell growth as compared with MTX. In vivo, intraperitonally administered pralatrexate at 60 mg/ kg twice weekly for three or four doses caused complete lymphoma regressions in 89, 56, and 30% of HT, RL, and SKI-DLBCL-1 xenografted mice, respectively, whereas a similar dosing of MTX at 40 mg/kg twice weekly did not produce complete regression. The posttreatment tumor diameter was also smaller in pralatrexate-treated animals.Verwenden
An antifolate with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.Definition
ChEBI: A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.Clinical Use
Pralatrexate, an injectable dihydrofolate reductase (DHFR) inhibitor, has a superior potency and toxicity profile compared to other DHFR inhibitors. In 2009, the compound was launched by Allos and approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. It is the first drug approved for this indication.70 In 2010, orphan drug designation was received in the E.U. for the treatment of cutaneous T-cell lymphoma (CTCL).Nebenwirkungen
The most common adverse reactions associated with pralatrexate are mucositis, thrombocytopenia, nausea, and fatigue. Folic acid and vitamin B12 supplements are administered as adjunct therapies to potentially reduce pralatrexate-related hematological toxicity and mucositis.10-Propargyl-10-deazaaminopterin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
10-Propargyl-10-deazaaminopterin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 183)Lieferanten
Firmenname | Telefon | Land | Produktkatalog | Edge Rate | |
---|---|---|---|---|---|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 |
sales@sjar-tech.com | China | 485 | 58 |
Shanghai Daken Advanced Materials Co.,Ltd | +86-371-+86-371-66670886 |
info@dakenam.com | China | 19805 | 58 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21628 | 55 |
Lianyungang happen teng technology co., LTD | 15950718863 |
wang666xt@163.com | CHINA | 295 | 58 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29858 | 58 |
Hubei Jusheng Technology Co.,Ltd. | 18871490254 |
linda@hubeijusheng.com | CHINA | 28172 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19552 | 58 |
CONIER CHEM AND PHARMA LIMITED | +8618523575427 |
sales@conier.com | China | 49732 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 |
marketing@targetmol.com | United States | 32159 | 58 |
HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 |
sales@hzclap.com | CHINA | 6312 | 58 |
146464-95-1()Verwandte Suche:
Lithiumdiisopropylamid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]amino]benzoyl]-L-glutaminsure
Glutaminsure
Benzoylisocyanat
Triamteren
Benzoylchlorid
Methylsalicylat
Nitrilotrimethylentris(phosphonsure)
Dibenzoylperoxid
Thiophanat-methyl
Trometamol
DIMETHYLAMINOPYRIDINE, POLYMER-BOUND
Dimethylcarbamoylchlorid
N,N-Dimethyl-phenylendiamin (p)
3-Brompropin
Glutamic acid
Methyl
Brommethan
- N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
- 10-Propargyl-10-deazaaminopterin
- L-Glutamic acid, N-(4-(1-((2,4-diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-
- Unii-A8Q8I19Q20
- FOLOTYN PRALATREXATE
- N-(4-{1-[(2,4-diaMinopteridin-6-yl)Methyl]but-3-yn-1-yl}benzoyl)-L-glutaMic acid
- N-[4-[1-[(2,4-DiaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-L-glutaMic Acid
- (2S)-2-(4-(1-(2,4-diaMinopteridin-6-yl)pent-4-yn-2-yl)benzaMido)pentanedioic acid
- Prelatrexate
- 10-Propargyl-10-deazaaMinopteri
- Pralatrexate(Folotyn)
- 10-Propargyl-10-deazaaminopterin N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
- N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid Pralatrexate
- Pralatrexate, >=98%
- Pralatrexat
- CS-2172
- Pralatrexate Impurity
- L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-
- 10-Propargyl-10-deazaaminopterin USP/EP/BP
- Pralatrexate (racemic)
- Pralatrexate
- Pdx
- Folotyn
- 146464-95-1 10-Propargyl-10-deazaaminopterin
- Pralatrexate (NSC 754230)
- Pralatrexate, 10 mM in DMSO
- 146464-95-1
- Amino Acids & Derivatives
- Aromatics
- Heterocycles
- Inhibitors
- Intermediates & Fine Chemicals
- Pharmaceuticals